Yu Mi Kang on the PCSK9 inhibitor Evolocumab & the FOURIER Trial, Neda Rasouli with insights on semaglutide in symptomatic peripheral artery disease & the STRIDE Trial, and more! episode artwork

EPISODE · Sep 5, 2025 · 42 MIN

Yu Mi Kang on the PCSK9 inhibitor Evolocumab & the FOURIER Trial, Neda Rasouli with insights on semaglutide in symptomatic peripheral artery disease & the STRIDE Trial, and more!

from Diabetes Care "On Air"

Welcome to episode no. 35 (September 2025) of Diabetes Care "On Air"—a new and different way to bring the research published in Diabetes Care to life. Join co-hosts Alice Cheng, MD, FRCPC, and Michael Rickels, MD, MS, as they discuss the latest and greatest content in the September 2025 issue of Diabetes Care and beyond. 3:05 Alice is joined by Yu Mi Kang, MD, PhD, endocrinologist at Brigham and Women's Hospital and instructor at Harvard University in Boston. The discuss her article, "Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial," available for free at doi.org/10.2337/dc25-0942. 14:10 Mike speaks with Neda Rasouli, MD, Professor of Medicine in the Division of Endocrinology, Metabolism, and Diabetes at the University of Anschutz Medical Campus. She shares insights from her article, "Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial," available for free at doi.org/10.2337/dc25-1082. 27:20 In the "Diabetes Care Rapid Exchange," Alice and Mike wrap up the episode by reviewing several interesting articles in the September 2025 issue of Diabetes Care. Studies highlighted in this segment include: Templeman et al. Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study doi.org/10.2337/dc25-0192 Yau et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease doi.org/10.2337/dc24-2811 Turner et al. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial doi.org/10.2337/dc25-0141 Gordon et al. Diabetes in Pregnancy and School-Age Developmental Outcomes for Offspring: A Statewide Retrospective Cohort Study doi.org/10.2337/dc25-0678 Witkowski et al. Predictors of Diabetes Outcomes at 1 Year After Islet Autotransplantation: Data From a Multicenter Cohort Study doi.org/10.2337/dc25-0620 Maagensen et al. Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes doi.org/10.2337/dc25-0737 To learn more about Diabetes Care, please visit diabetesjournals.org/care. Interested in submitting cover art to the journal? Please visit https://diabetesjournals.org/care/pages/submit_a_cover_image.

Episode metadata supplied by the publisher feed · Published Sep 5, 2025

Embed this episode

Ready to play

Yu Mi Kang on the PCSK9 inhibitor Evolocumab & the FOURIER Trial, Neda Rasouli with insights on semaglutide in symptomatic peripheral artery disease & the STRIDE Trial, and more!

0:00 42:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Care "On Air"?

This episode is 42 minutes long.

When was this Diabetes Care "On Air" episode published?

This episode was published on September 5, 2025.

Can I download this Diabetes Care "On Air" episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!